Bimatoprost
- Generic Name
- Bimatoprost
- Brand Names
- Durysta, Latisse, Lumigan
- Drug Type
- Small Molecule
- Chemical Formula
- C25H37NO4
- CAS Number
- 155206-00-1
- Unique Ingredient Identifier
- QXS94885MZ
- Background
Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma. Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth. It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.
- Indication
Bimatoprost is used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
These patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatments.
Bimatoprost is also indicated to treat eyelash hypotrichosis.
- Associated Conditions
- Hypotrichosis of the eyelashes, Increased Intra Ocular Pressure (IOP)
- Associated Therapies
- -
Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma
- Conditions
- GlaucomaQuality of Life (QOL)
- Interventions
- Drug: Triple combination formulaDrug: Bimatoprost .03% sterile ophthalmic solution
- First Posted Date
- 2025-01-07
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Federal University of São Paulo
- Target Recruit Count
- 40
- Registration Number
- NCT06761313
- Locations
- 🇧🇷
Federal University of São Paulo, São Paulo, SP, Brazil
Treatment of Hypopigmented Scars With Bimatoprost
- Conditions
- Hypopigmented ScarHypopigmented SkinBurn ScarPigmentation DisorderScarsScarringCicatrix, HypertrophicBurns LaserCicatrix
- Interventions
- Drug: SalineDrug: Bimatoprost
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Medstar Health Research Institute
- Target Recruit Count
- 25
- Registration Number
- NCT06122090
- Locations
- 🇺🇸
MedStar Washington Hospital Center, Washington, District of Columbia, United States
Effect of Microneedling, Bimatoprost and Excimer in Vitiligo Treatment
- Conditions
- Vitiligo
- Interventions
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 4
- Registration Number
- NCT04738149
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 485
- Registration Number
- NCT03825380
- Locations
- 🇪🇪
Hospital, Tallinn, Estonia
A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2019-02-25
- Lead Sponsor
- ForSight Vision5, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT02742649
- Locations
- 🇵🇦
Clinica de Ojos Orillac - Calvo, Panama City, Panama
Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)
- First Posted Date
- 2016-02-08
- Last Posted Date
- 2017-03-17
- Lead Sponsor
- Allergan
- Target Recruit Count
- 53
- Registration Number
- NCT02676310
- Locations
- 🇺🇸
J&S Studies Inc., College Station, Texas, United States
🇺🇸E&R Research Foundation, Lynchburg, Virginia, United States
🇺🇸DermResearch, LLC, Austin, Texas, United States
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
- Conditions
- Primary Open-Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- ForSight Vision5, Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT02537015
- Locations
- 🇺🇸
Sall Medical Research Center, Artesia, California, United States
🇺🇸Total Eye Care, Memphis, Tennessee, United States
🇺🇸Eye Research Foundation, Newport Beach, California, United States
Stop Retinal Ganglion Cell Dysfunction Study
- Conditions
- Glaucoma
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 500
- Registration Number
- NCT02390284
- Locations
- 🇺🇸
Bascom Palmer Eye Institute - University of Miami, Miami, Florida, United States
Dose-Ranging Study of the Bimatoprost Ocular Insert
- Conditions
- Primary Open-Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2015-02-09
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- ForSight Vision5, Inc.
- Target Recruit Count
- 156
- Registration Number
- NCT02358369
- Locations
- 🇺🇸
Vold Vision, Fayetteville, Arkansas, United States
🇺🇸Total Eye Care, Memphis, Tennessee, United States
🇺🇸University of Eye Specialists, Maryville, Tennessee, United States
Topical Bimatoprost Effect on Androgen Dependent Hair Follicles
- Conditions
- Male Pattern Hair LossAndrogenetic Alopecia
- Interventions
- Drug: BimatoprostDrug: Placebo
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2014-09-05
- Lead Sponsor
- Duke University
- Target Recruit Count
- 33
- Registration Number
- NCT02170662
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.